TG Therapeutics

is a biopharmaceutical company focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders.

Product Pipeline

TG-1101 (UBLITUXIMAB)

Ublituximab is a novel, glyco-engineered monoclonal antibody that targets a specific and unique epitope on the B-lymphocyte CD20 antigen, currently in clinical development for hematologic disorders.

TGR-1202

TGR-1202 is an orally available PI3K delta inhibitor targeting the delta isoform with nanomolar potency and several fold selectivity over other PI3K isoforms.

For Investors

NASDAQ: TGTX
Stock Quote at: Aug 29, 4:00PM EDT

Last: $8.48

Change: ($0.07) (0.82%)

Quotes provided by Google - Min 15 minute delay